Trade

with

Keryx Biopharmaceuticals Inc
(NASDAQ: KERX)
AdChoices
16.07
+0.16
+0.97%
After Hours :
-
-
-

Open

15.61

Previous Close

15.91

Volume (Avg)

28.29k (2.46M)

Day's Range

15.54-16.07

52Wk Range

10.01-18.48

Market Cap.

1.46B

Dividend Rate ( Yield )

-

Beta

3.17

Shares Outstanding

91.97M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 7.00M

    • Net Income

    • -46.73M

    • Market Cap.

    • 1.46B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -692.63

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 3.17

    • Forward P/E

    • -104.17

    • Price/Sales

    • 136.99

    • Price/Book Value

    • 11.76

    • Price/Cash flow

    • -25.45

      • EBITDA

      • -47.03M

      • Return on Capital %

      • -60.76

      • Return on Equity %

      • -70.11

      • Return on Assets %

      • -60.76

      • Book Value/Share

      • 1.35

      • Shares Outstanding

      • 91.97M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 25.00

        • Credit Rating

        • -

        • Analysts

        • 5

        • EPS Estimate

        • -0.15

        • Cashflow Estimate

        • 1.16

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 40.40

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -692.63

            • 39.38

            • Net Profit Margin

            • -692.63

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 7.47

              • 2.92

              • Quick Ratio

              • 7.41

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.15

              • 2.21

              • Book Value/Share

              • 1.35

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -19.31

                • 196.08

                • P/E Ratio 5-Year High

                • -22.97

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.59

                • 124.82

                • Price/Sales Ratio

                • 133.33

                • 9.12

                • Price/Book Value

                • 11.47

                • 8.26

                • Price/Cash Flow Ratio

                • -25.45

                • 47.39

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -70.11

                        (-77.00)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -60.76

                        (-58.00)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -70.11

                        (-77.00)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.09

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -47.08M
                      Operating Margin
                      -672.61
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -25.45
                      Ownership

                      Institutional Ownership

                      83.39%

                      Top 10 Institutions

                      51.30%

                      Mutual Fund Ownership

                      37.77%

                      Float

                      88.08%

                      5% / Insider Ownership

                      6.68%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        3,125,768

                      • 5.90

                      • 3.40

                      • Oak Ridge Small Cap Growth Fund

                      •  

                        2,094,900

                      • 51.11

                      • 2.28

                      • Franklin Biotechnology Discovery

                      •  

                        2,044,000

                      • 43.09

                      • 2.24

                      • Vanguard Small Cap Index

                      •  

                        1,594,916

                      • 90.96

                      • 1.74

                      • Vanguard Total Stock Mkt Idx

                      •  

                        1,493,420

                      • 0.00

                      • 1.63

                      • iShares Russell 2000 (AU)

                      •  

                        1,415,419

                      • -1.02

                      • 1.74

                      • SPDR® S&P Biotech ETF

                      •  

                        1,234,675

                      • 3.59

                      • 1.52

                      • Eagle Small Cap Growth Fund

                      •  

                        1,217,798

                      • -10.97

                      • 1.33

                      • Franklin Biotechnology Discovery Fund

                      •  

                        1,107,300

                      • 22.64

                      • 1.21

                      • UBS (Lux) EF Biotech (USD)

                      •  

                        1,079,996

                      • 0.00

                      • 1.18

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Vanguard Group, Inc.

                      •  

                        4,160,274

                      • +0.97%

                      • 4.53

                      • Deerfield Management Co

                      •  

                        3,884,409

                      • +176.84%

                      • 4.23

                      • Fidelity Management and Research Company

                      •  

                        3,766,433

                      • +4.19%

                      • 4.11

                      • Sectoral Asset Management Inc

                      •  

                        3,741,656

                      • +5.77%

                      • 4.08

                      • Camber Capital Management LLC

                      •  

                        3,000,000

                      • +140.00%

                      • 3.27

                      • Franklin Advisers, Inc.

                      •  

                        2,946,900

                      • -3.14%

                      • 3.21

                      • State Street Corp

                      •  

                        2,631,452

                      • -6.85%

                      • 2.87

                      • BlackRock Fund Advisors

                      •  

                        2,565,844

                      • -0.31%

                      • 2.80

                      • Oak Ridge Investments, LLC

                      •  

                        2,081,792

                      • +0.71%

                      • 2.27

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Growth

                      Keryx Biopharmaceuticals, Inc., was incorporated in Delaware in October 1998. The Company is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of re...morenal disease. It is developing ZerenexTM an oral, ferric iron-based compound. It has completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease, or CKD, on dialysis, conducted pursuant to a Special Protocol Assessment, or SPA, agreement with the U.S. Food and Drug Administration, or FDA. Its New Drug Application, or NDA, is currently under review by the FDA with an assigned Prescription Drug User Fee Act, or PDUFA. It has also completed a U.S.-based Phase 2 study of...more Zerenex for the management of elevated serum phosphorus levels and iron deficiency anemia in subjects with Stage 3 to 5 NDD-CKD. Currently, its only drug candidate is Zerenex. Its competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions.lessless

                      Key People

                      Ron Bentsur

                      CEO/Director

                      Michael P. Tarnok

                      Director/Chairman of the Board

                      James F. Oliviero

                      CFO/Chief Accounting Officer/Secretary/Treasurer

                      Greg Madison

                      COO/Executive VP

                      Jack Kaye

                      Director

                      • Keryx Biopharmaceuticals Inc

                      • 750 Lexington Avenue

                      • New York, NY 10022

                      • USA.Map

                      • Phone: +1 212 531-5965

                      • Fax: +1 212 531-5961

                      • keryx.com

                      Incorporated

                      1998

                      Employees

                      88

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: